E-LIB Suche - Ergebnisse für: Westin, J.

1

ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF ..:

Westin, J. ; Jacobson, C. A. ; Chavez, J. C....
Hematological Oncology. 41 (2023) S2 - p. 171-173 , 2023

Link: https://doi.org/10.1002/..

2

A Phase II Investigator Initiated Study of Acalabrutinib, L..:

Strati, P. ; Feng, L. ; Westin, J....
Hematological Oncology. 41 (2023) S2 - p. 383-383 , 2023

Link: https://doi.org/10.1002/..

3

Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residu..:

Miles, B. R. ; Mao, D. ; Vardhanabhuti, S....
Hematological Oncology. 41 (2023) S2 - p. 329-330 , 2023

Link: https://doi.org/10.1002/..

4

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFA..:

Westin, J. ; Strati, P. ; Chihara, D....
Hematological Oncology. 41 (2023) S2 - p. 837-838 , 2023

Link: https://doi.org/10.1002/..

5

CC‐99282 plus R‐CHOP in patients (pts) with previously untr..:

Munoz, J. ; Hoffmann, M. ; Westin, J....
Hematological Oncology. 41 (2023) S2 - p. 584-586 , 2023

Link: https://doi.org/10.1002/..

6

PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBST..:

Lue, J. K. ; Stevens, D. A. ; Ayers, E....
Hematological Oncology. 41 (2023) S2 - p. 808-809 , 2023

Link: https://doi.org/10.1002/..

7

Outcomes and Toxicities in Patients with Diffuse Large B-Ce..:

Cha, E. ; Manzar, G.S. ; Corrigan, K.L....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e460 , 2023

Link: https://doi.org/10.1016/..

8

OC-055 Mesh infections – frequency, risk factors and treatm..:

Westin, L ; Sandblom, G ; Gunnarsson, U.
British Journal of Surgery. 110 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

9

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYS..:

Roschewski, M. ; Kurtz, D. M. ; Westin, J....
Hematological Oncology. 41 (2023) S2 - p. 177-179 , 2023

Link: https://doi.org/10.1002/..

10

ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDE..:

Jain, P. ; Ok, C. y. ; Fetooh, A....
Hematological Oncology. 41 (2023) S2 - p. 150-151 , 2023

Link: https://doi.org/10.1002/..

11

Characterization of Lymphopenia during Bridging Radiation T..:

Manzar, G.S. ; Wu, S.Y. ; Dudzinski, S.O....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. S53-S54 , 2023

Link: https://doi.org/10.1016/..

12

IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐S..:

Wang, M. L. ; Lee, H. J. ; Fetooh, A....
Hematological Oncology. 41 (2023) S2 - p. 152-153 , 2023

Link: https://doi.org/10.1002/..

13

BONE MARROW VOLUME IRRADIATED AND RISK OF CYTOPENIAS IN AGG..:

Manzar, G. S. ; Dabaja, B. S. ; Wu, S. Y....
Hematological Oncology. 41 (2023) S2 - p. 222-223 , 2023

Link: https://doi.org/10.1002/..

14

Outcomes with Bridging Radiation Therapy Prior to CAR-T Cel..:

Manzar, G.S. ; Wu, S.Y. ; Dudzinski, S.O....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e483-e484 , 2023

Link: https://doi.org/10.1016/..

15

SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VE..:

Pavlovsky, A. ; Westin, J. ; Olszewski, A. J...
Hematological Oncology. 41 (2023) S2 - p. 170-171 , 2023

Link: https://doi.org/10.1002/..